Strahlentherapie und Onkologie

, Volume 189, Issue 6, pp 502–507 | Cite as

125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region

  • M.-W. Huang
  • L. Zheng
  • S.-M. Liu
  • Y. Shi
  • J. Zhang
  • G.-Y. Yu
  • J.-G. ZhangEmail author
Original article


Background and purpose

This retrospective study was to evaluate the local control and survival of 125I brachytherapy for recurrent and/or locally advanced adenoid cystic carcinoma (ACC) of the oral and maxillofacial region.

Patients and methods

A total of 38 patients with recurrent and/or locally advanced ACC of the oral and maxillofacial region received 125I brachytherapy alone from 2001–2010. Twenty-nine were recurrent cases following previous surgery and radiation therapy. The other 9 cases involved primary tumors. Overall, 12 tumors were located in the major salivary glands, 12 in the minor salivary glands, and 14 in the paranasal region, the nasal cavity or the skull base. The prescribed dose was 100–160 Gy.


Patients were followed for 12–122 months (median 51 months). The 2-, 5-, and 10-year local tumor control rates were 86.3, 59, and 31.5 %, respectively. The 2-, 5-, and 10-year overall survival rates were 92.1, 65 and 34.1 %, respectively. Tumors > 6 cm had significantly lower local control and survival rates. No severe complications were observed during follow-up.


125I brachytherapy is a feasible and effective modality for the treatment of locally advanced unresectable or recurrent ACC.


Brachytherapy Adenoid cystic carcinoma Oral and maxillofacial Salivary gland neoplasms Head and neck neoplasms 

Alleinige 125I Brachytherapie zur Behandlung rezidivierter oder lokal fortgeschrittener adenoid-zystischen Karzinome in Mund-, -Kiefer- und Gesichtsbereich


Hintergrund und Ziel

Diese retrospektive Studie untersucht die lokale Kontrolle und Überlebensrate durch Brachytherapie mit 125I für das rezidivierte und/oder lokal fortgeschrittene adenoid-zystische Karzinom (ACC) der oralen und maxillofazialen Region.

Patienten und Methoden

Von 2001 bis 2010 wurden 38 Patienten mit rezidiviertem und/oder lokal fortgeschrittenem ACC im Mund, -Kiefer- und Gesichtsbereich durch 125I-Brachytherapie behandelt. Davon handelte es sich in 29 Fällen um Rezidive nach chirurgischer Tumorentfernung und Strahlentherapie. Die übrigen 9 Fälle waren primäre Tumormanifestationen. Bei 12 Patienten war die Tumorlokalisation in den großen Speicheldrüsen, bei weiteren 12 Patienten in den kleinen Speicheldrüsen und bei 14 Patienten in der paranasalen Region, der Nasenhöhle oder der Schädelbasis. Die applizierte Strahlendosis betrug zwischen 100 und 160 Gy. Der Beobachtungszeitraum lag zwischen 12 und 122 Monaten (Median 51 Monate).


Bei den lokalen Tumorkontrollen nach 2, 5 und 10 Jahren waren jeweils 86,3%, 59% und 31,5 % tumorfrei. Die 2-, 5- und 10-Jahres-Überlebensraten betrugen 92,1%, 65% und 34,1 %. Tumoren > 6 cm zeigten signifikant niedrigere lokale Tumorfreiheit und niedrigere Überlebensraten. Während des Follow-up-Zeitraums wurden keine schweren Komplikationen beobachtet.


Die 125I-Brachytherapie ist praktikabel, wirksam und stellt eine Modalität in der Behandlung eines lokal fortgeschrittenem inoperablem oder rezidiviertem ACC dar.


Brachytherapie Adenoid-zystisches Karzinom Oral und maxillofazial Speicheldrüsenneoplasien Kopf- und Halsneoplasien 



This study was partially supported by the Capital Development Fund of Beijing (2005). We acknowledge Prof. Zhi-Gang Cai (Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology) for his assistance in the preparation and review of this article.

Conflict of interest

On behalf of all authors, the corresponding author states that there are no conflicts of interest.


  1. 1.
    Ashamalla H, Rafla S, Zaki B et al (2002) Radioactive gold grain implants in recurrent and locally advanced head-and-neck cancers. Brachytherapy 1:161–166PubMedCrossRefGoogle Scholar
  2. 2.
    Avery CM, Moody AB, McKinna FE et al (2000) Combined treatment of adenoid cystic carcinoma of the salivary glands. Int J Oral Maxillofac Surg 29:277–279PubMedCrossRefGoogle Scholar
  3. 3.
    Ayukawa F, Shibuya H, Yoshimura R et al (2007) Curative brachytherapy for recurrent/residual tongue cancer. Strahlenther Onkol 183:133–137PubMedCrossRefGoogle Scholar
  4. 4.
    Balamucki CJ, Amdur RJ, Werning JW et al (2012) Adenoid cystic carcinoma of the head and neck. Am J Otolaryngol 33:510–518PubMedCrossRefGoogle Scholar
  5. 5.
    Bianchi B, Copelli C, Cocchi R et al (2008) Adenoid cystic carcinoma of intraoral minor salivary glands. Oral Oncol 44:1026–1031PubMedCrossRefGoogle Scholar
  6. 6.
    Chen AM, Bucci MK, Weinberg V et al (2006) Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 66:152–159PubMedCrossRefGoogle Scholar
  7. 7.
    Cowie VJ, Pointon RCS (1984) Adenoid cystic carcinoma of the salivary glands. Clin Radiol 35:331–333PubMedCrossRefGoogle Scholar
  8. 8.
    Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedCrossRefGoogle Scholar
  9. 9.
    Douglas JG, Laramore GE, Austin-Seymour M et al (2000) Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 46:551–557PubMedCrossRefGoogle Scholar
  10. 10.
    Emami B, Marks JE (1983) Re-irradiation of recurrent carcinoma of the head and neck by afterloading interstitial 192Ir implant. Laryngoscope 93:1345–1347PubMedGoogle Scholar
  11. 11.
    Glaser MG, Leslie MD, Coles I, Cheesman AD (1995) Iodine seeds in the treatment of slowly proliferating tumours in the head and neck region. Clin Oncol 7:106–109CrossRefGoogle Scholar
  12. 12.
    Goldner G, Pötter R, Battermann JJ et al (2012) Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients. Strahlenther Onkol 188:305–310PubMedCrossRefGoogle Scholar
  13. 13.
    Grabenbauer GG, Rödel C, Brunner T et al (2001) Interstitial brachytherapy with Ir-192 low-dose-rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Review of 318 patients treated between 1985 and 1997. Strahlenther Onkol 177:338–344PubMedCrossRefGoogle Scholar
  14. 14.
    Haddad A, Enepekides DJ, Manolidis S, Black M (1995) Adenoid cystic carcinoma of the head and neck: a clinicopathologic study of 37 cases. J Otolaryngol 24:201–205PubMedGoogle Scholar
  15. 15.
    Harrison LB, Armstrong JG, Spiro RH et al (1990) Postoperative radiation therapy for major salivary gland malignancies. J Surg Oncol 45:52–55PubMedCrossRefGoogle Scholar
  16. 16.
    Iseli TA, Karnell LH, Graham SM et al (2009) Role of radiotherapy in adenoid cystic carcinoma of the head and neck. J Laryngol Otol 123:1137–1144PubMedCrossRefGoogle Scholar
  17. 17.
    Jiang YL, Meng N, Wang JJ et al (2010) CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers. Radiat Oncol 5:68PubMedCrossRefGoogle Scholar
  18. 18.
    Julow J, Viola A, Major T et al (2004) Iodine-125 brachytherapy of brain stem tumors. Strahlenther Onkol 180:449–454PubMedCrossRefGoogle Scholar
  19. 19.
    Khan AJ, DiGiovanna MP, Ross DA et al (2001) Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 96:149–158PubMedCrossRefGoogle Scholar
  20. 20.
    Kim KH, Sung MW, Chung PS et al (1994) Adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 120:721–726PubMedCrossRefGoogle Scholar
  21. 21.
    Kim GE, Park HC, Keum KC et al (1999) Adenoid cystic carcinoma of the maxillary antrum. Am J Otolaryngol 20:77–84PubMedCrossRefGoogle Scholar
  22. 22.
    Ko YH, Lee MA, Hong YS et al (2007) Prognostic factors affecting the clinical outcome of adenoid cystic carcinoma of the head and neck. Jpn J Clin Oncol 37:805–811PubMedCrossRefGoogle Scholar
  23. 23.
    Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE (2004) Adenoid cystic carcinoma of the head and neck—a 20 years experience. Int J Oral Maxillofac Surg 33:25–31PubMedCrossRefGoogle Scholar
  24. 24.
    Konno A, Ishikawa K, Numata T et al (1998) Analysis of factors affecting long-term treatment results of adenoid cystic carcinoma of the nose and paranasal sinuses. Acta Otolaryngol Suppl 537:67–74PubMedGoogle Scholar
  25. 25.
    Laurie SA, Ho AL, Fury MG et al (2011) Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 12:815–824PubMedCrossRefGoogle Scholar
  26. 26.
    Le QT, Birdwell S, Terris DJ et al (1999) Postoperative irradiation of minor salivary gland malignancies of the head and neck. Radiother Oncol 52:165–171PubMedCrossRefGoogle Scholar
  27. 27.
    Leafstedt SW, Gaeta JF, Sako K et al (1971) Adenoid cystic carcinoma of major and minor salivary glands. Am J Surg 122:756–762PubMedCrossRefGoogle Scholar
  28. 28.
    Li Q, Xu T, Gao JM et al (2011) Surgery alone provides long-term survival rates comparable to those of surgery plus postoperative for patients with adenoid cystic carcinoma of the palate. Oral Oncol 47:170–173PubMedCrossRefGoogle Scholar
  29. 29.
    Lopes MA, Santos GC, Kowalski LP (1998) Multivariate survival analysis of 128 cases of oral cavity minor salivary gland carcinoma. Head Neck 20:699–706PubMedCrossRefGoogle Scholar
  30. 30.
    Mendenhall WM, Morris CG, Amdur RJ et al (2004) Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 26:154–162PubMedCrossRefGoogle Scholar
  31. 31.
    Miglianico L, Eschwege F, Marandas P, Wibault P (1987) Cervico-facial adenoid cystic carcinoma: study of 102 cases. Influence of radiation therapy. Int J Radiat Oncol Biol Phys 13:673–678PubMedCrossRefGoogle Scholar
  32. 32.
    Mücke T, Tannapfel A, Kesting MR et al (2010) Adenoid cystic carcinomas of minor salivary glands. Auris Nasus Larynx 37:615–620PubMedCrossRefGoogle Scholar
  33. 33.
    Pandey M, Thomas S, Mathew A, Nair MK (2003) Malignant tumours of the minor salivary glands: a survival analysis of 17 years from a tertiary referral cancer centre. J Postgrad Med 49:25–58PubMedCrossRefGoogle Scholar
  34. 34.
    Park RI, Liberman FZ, Lee DJ et al (1991) Iodine-125 seed implantation as an adjunct to surgery in advanced recurrent squamous cancer of the head and neck. Laryngoscope 101:405–410PubMedCrossRefGoogle Scholar
  35. 35.
    Peters N, Wieners G, Pech M et al (2008) CT-guided interstitial brachytherapy of primary and secondary lung malignancies: results of a prospective phase II trial. Strahlenther Onkol 184:296–301PubMedCrossRefGoogle Scholar
  36. 36.
    Prokopakis EP, Snyderman CH, Hanna EY et al (1999) Risk factors for local recurrence of adenoid cystic carcinoma: the role of postoperative radiation therapy. Am J Otolaryngol 20:281–286PubMedCrossRefGoogle Scholar
  37. 37.
    Puthawala A, Nisar Syed AM, Gamie S et al (2001) Interstitial low-dose rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results. Int J Radiat Oncol Biol Phys 51:354–362PubMedCrossRefGoogle Scholar
  38. 38.
    Rapidis AD, Givalos N, Gakiopoulou H et al (2005) Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol 41:328–335PubMedCrossRefGoogle Scholar
  39. 39.
    Renehan A, Gleave EN, Hancock BD et al (1996) Long-term follow-up of over 1000 patients with salivary gland tumors treated in a single centre. Br J Surg 83:1750–1754PubMedCrossRefGoogle Scholar
  40. 40.
    Rhee CS, Won TB, Lee CH et al (2006) Adenoid cystic carcinoma of the sinonasal tract: treatment results. Laryngoscope 116:982–986PubMedCrossRefGoogle Scholar
  41. 41.
    Richter J, Baier K, Flentje M (2008) Comparison of 60cobalt and 192iridium sources in high dose rate afterloading brachytherapy. Strahlenther Onkol 184:187–192PubMedCrossRefGoogle Scholar
  42. 42.
    Ruge MI, Kocher M, Maarouf M et al (2011) Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases. Strahlenther Onkol 187:7–14PubMedCrossRefGoogle Scholar
  43. 43.
    Russell JD, Bleach NR, Glaser M, Cheesman AD (1993) Brachytherapy for recurrent nasopharyngeal and nasoethmoidal tumours. J Laryngol Otol 107:115–120PubMedCrossRefGoogle Scholar
  44. 44.
    Stannard C, Maree G, Munro R et al (2011) Iodine-125 orbital brachytherapy with a prosthetic implant in situ. Strahlenther Onkol 187:322–327PubMedCrossRefGoogle Scholar
  45. 45.
    Stannard CE, Hering E, Hough J et al (2004) Post-operative treatment of malignant salivary gland tumors of the palate with iodine-125 brachytherapy. Radiother Oncol 73:307–311PubMedCrossRefGoogle Scholar
  46. 46.
    Strnad V (2004) Treatment of oral cavity and oropharyngeal cancer. Indications, technical aspects, and results of interstitial brachytherapy. Strahlenther Onkol 180:710–717PubMedCrossRefGoogle Scholar
  47. 47.
    Umeda M, Nishimatsu N, Yokoo S et al (2000) The role of radiotherapy for patients with adenoid cystic carcinoma of the salivary gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89:724–729PubMedCrossRefGoogle Scholar
  48. 48.
    Vattemi E, Graiff C, Sava T et al (2008) Systemic therapies for recurrent and/or metastatic salivary gland cancers. Expert Rev Anticancer Ther 8:393–402PubMedCrossRefGoogle Scholar
  49. 49.
    Vikram B, Hilaris B (1984) Transnasal permanent interstitial implantation for carcinoma of the nasopharynx. Int J Radiat Oncol Biol Phys 10:153–155PubMedCrossRefGoogle Scholar
  50. 50.
    Wiseman SM, Popat SR, Rigual NR et al (2002) Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity: a 40-year review of 35 cases. Ear Nose Throat J 81:510–514, 516–517PubMedGoogle Scholar
  51. 51.
    Zhang J, Zhang JG, Song TL et al (2008) 125I seed implant brachytherapy-assisted surgery with preservation of facial nerve for treatment of malignant parotid gland tumors. Int J Oral Maxillofac Surg 37:515–520PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2013

Authors and Affiliations

  • M.-W. Huang
    • 1
  • L. Zheng
    • 1
  • S.-M. Liu
    • 1
  • Y. Shi
    • 1
  • J. Zhang
    • 1
  • G.-Y. Yu
    • 1
  • J.-G. Zhang
    • 1
    Email author
  1. 1.Department of Oral and Maxillofacial SurgeryPeking University School and Hospital of StomatologyBeijingP. R. China

Personalised recommendations